329 related articles for article (PubMed ID: 29052093)
1. Emerging small molecule approaches to enhance the antimyeloma benefit of proteasome inhibitors.
Driscoll JJ; Brailey M
Cancer Metastasis Rev; 2017 Dec; 36(4):585-598. PubMed ID: 29052093
[TBL] [Abstract][Full Text] [Related]
2. The proteasome and proteasome inhibitors in multiple myeloma.
Gandolfi S; Laubach JP; Hideshima T; Chauhan D; Anderson KC; Richardson PG
Cancer Metastasis Rev; 2017 Dec; 36(4):561-584. PubMed ID: 29196868
[TBL] [Abstract][Full Text] [Related]
3. Proteasome inhibitors for multiple myeloma.
Okazuka K; Ishida T
Jpn J Clin Oncol; 2018 Sep; 48(9):785-793. PubMed ID: 30102324
[TBL] [Abstract][Full Text] [Related]
4. Therapeutically targeting the SUMOylation, Ubiquitination and Proteasome pathways as a novel anticancer strategy.
Driscoll JJ; Dechowdhury R
Target Oncol; 2010 Dec; 5(4):281-9. PubMed ID: 21125340
[TBL] [Abstract][Full Text] [Related]
5. Targeting Deubiquitinating Enzymes and Autophagy in Cancer.
Mooneyham A; Bazzaro M
Methods Mol Biol; 2017; 1513():49-59. PubMed ID: 27807830
[TBL] [Abstract][Full Text] [Related]
6. Targeting the Immune Niche within the Bone Marrow Microenvironment: The Rise of Immunotherapy in Multiple Myeloma.
Podar K; Jager D
Curr Cancer Drug Targets; 2017; 17(9):782-805. PubMed ID: 28201977
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of the ʟ-glutamine transporter ASCT2 sensitizes plasma cell myeloma cells to proteasome inhibitors.
Prelowska MK; Mehlich D; Ugurlu MT; Kedzierska H; Cwiek A; Kosnik A; Kaminska K; Marusiak AA; Nowis D
Cancer Lett; 2021 Jun; 507():13-25. PubMed ID: 33713737
[TBL] [Abstract][Full Text] [Related]
8. Dual Inhibition of EZH2 and EZH1 Sensitizes PRC2-Dependent Tumors to Proteasome Inhibition.
Rizq O; Mimura N; Oshima M; Saraya A; Koide S; Kato Y; Aoyama K; Nakajima-Takagi Y; Wang C; Chiba T; Ma A; Jin J; Iseki T; Nakaseko C; Iwama A
Clin Cancer Res; 2017 Aug; 23(16):4817-4830. PubMed ID: 28490465
[No Abstract] [Full Text] [Related]
9. Role of Immunotherapy in Targeting the Bone Marrow Microenvironment in Multiple Myeloma: An Evolving Therapeutic Strategy.
Chung C
Pharmacotherapy; 2017 Jan; 37(1):129-143. PubMed ID: 27870103
[TBL] [Abstract][Full Text] [Related]
10. Immunoproteasome-selective and non-selective inhibitors: A promising approach for the treatment of multiple myeloma.
Ettari R; Zappalà M; Grasso S; Musolino C; Innao V; Allegra A
Pharmacol Ther; 2018 Feb; 182():176-192. PubMed ID: 28911826
[TBL] [Abstract][Full Text] [Related]
11. Seeking Convergence and Cure with New Myeloma Therapies.
Choudhry P; Galligan D; Wiita AP
Trends Cancer; 2018 Aug; 4(8):567-582. PubMed ID: 30064664
[TBL] [Abstract][Full Text] [Related]
12. Updates to the drug-resistant mechanism of proteasome inhibitors in multiple myeloma.
Bai Y; Su X
Asia Pac J Clin Oncol; 2021 Feb; 17(1):29-35. PubMed ID: 32920949
[TBL] [Abstract][Full Text] [Related]
13. Increased resistance to proteasome inhibitors in multiple myeloma mediated by cIAP2--implications for a combinatorial treatment.
Fristedt Duvefelt C; Lub S; Agarwal P; Arngården L; Hammarberg A; Maes K; Van Valckenborgh E; Vanderkerken K; Jernberg Wiklund H
Oncotarget; 2015 Aug; 6(24):20621-35. PubMed ID: 26036313
[TBL] [Abstract][Full Text] [Related]
14. Small-molecule control of intracellular protein levels through modulation of the ubiquitin proteasome system.
Buckley DL; Crews CM
Angew Chem Int Ed Engl; 2014 Feb; 53(9):2312-30. PubMed ID: 24459094
[TBL] [Abstract][Full Text] [Related]
15. Emerging biological insights and novel treatment strategies in multiple myeloma.
Gentile M; Recchia AG; Mazzone C; Morabito F
Expert Opin Emerg Drugs; 2012 Sep; 17(3):407-38. PubMed ID: 22920042
[TBL] [Abstract][Full Text] [Related]
16. Resistance to proteasome inhibitors and other targeted therapies in myeloma.
Wallington-Beddoe CT; Sobieraj-Teague M; Kuss BJ; Pitson SM
Br J Haematol; 2018 Jul; 182(1):11-28. PubMed ID: 29676460
[TBL] [Abstract][Full Text] [Related]
17. Limited treatment options in refractory multiple myeloma: promising therapeutic developments.
Oriol A; Abril L; Ibarra G; Senin A
Expert Rev Anticancer Ther; 2020 Jan; 20(1):31-44. PubMed ID: 31865804
[No Abstract] [Full Text] [Related]
18. Proteasome-associated deubiquitinases and cancer.
Mofers A; Pellegrini P; Linder S; D'Arcy P
Cancer Metastasis Rev; 2017 Dec; 36(4):635-653. PubMed ID: 29134486
[TBL] [Abstract][Full Text] [Related]
19. Ubiquitin-proteasome system as a target for anticancer treatment-an update.
Kim YJ; Lee Y; Shin H; Hwang S; Park J; Song EJ
Arch Pharm Res; 2023 Jul; 46(7):573-597. PubMed ID: 37541992
[TBL] [Abstract][Full Text] [Related]
20. Discovering proteasomal deubiquitinating enzyme inhibitors for cancer therapy: lessons from rational design, nature and old drug reposition.
Patel K; Ahmed ZS; Huang X; Yang Q; Ekinci E; Neslund-Dudas CM; Mitra B; Elnady FA; Ahn YH; Yang H; Liu J; Dou QP
Future Med Chem; 2018 Sep; 10(17):2087-2108. PubMed ID: 30066579
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
